Comment
Author: Admin | 2025-04-28
Filed First applicant approval Last patent expiry 180 day status 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg 10 Jul, 2019 18 11 Aug, 2022 12 Oct, 2032 Deferred Alternative Brands for Rexulti Rexulti which is used for treating major depressive disorder (MDD) and schizophrenia in adults and pediatric patients ages 13 years and older., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively. Drug Owner Drug Name Treatment Area Alkermes Inc Aristada Used for managing symptoms of schizophrenia through various methods of administration. Aristada Initio Kit Used for managing symptoms of schizophrenia.Indivior Perseris Kit Used for treating schizophrenia.Intra-cellular Caplyta Used for treating schizophrenia, bipolar depression, and bipolar disorder by modulating serotonin and dopamine receptor activity.Janssen Pharms Invega Trinza used for managing symptoms of schizophrenia in patients who have missed doses or need to restart treatment. Invega Sustenna used for treating schizophrenia and schizoaffective disorder. Risperdal Consta Used for maintenance treatment of bipolar I disorder and treatment of schizophrenia.Otsuka Abilify Used for treating manic episodes in bipolar disorder, major depressive disorder, irritability in autistic disorder, and maintaining stability in schizophrenia. Abilify Asimtufii Used for managing symptoms of bipolar I disorder and schizophrenia with extended-release injectable suspension. Abilify Mycite Kit used for acute treatment of manic and mixed episodes associated with bipolar I disorder, adjunctive treatment of major depressive disorder (MDD), and treatment of schizophrenia.Otsuka Pharm Co Ltd Abilify Maintena Kit Used for treating bipolar 1 disorder and schizophrenia, including during acute episodes.Sunovion Pharms Inc Latuda used for treating bipolar depression, major depressive episodes, and schizophrenia with improvement in attention function, negative symptoms, and cognitive dysfunction.Teva Uzedy Used for managing symptoms of schizophrenia. About Rexulti Rexulti is a drug owned by Otsuka Pharmaceutical Co Ltd. It is used for treating major depressive disorder (MDD) and schizophrenia in adults and pediatric patients ages 13 years and older. Rexulti uses Brexpiprazole as an active ingredient. Rexulti was launched by Otsuka in 2015. Rexulti was approved by FDA for market use on 10 July, 2015. NCE-1 date: NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph
Add Comment